RIGI and breast cancer: The results revealed that silencing AIM2, RIG-I, or MDA-5 did not significantly reduce IFN-β secretion from the “BC@Z-M + L”-treated 4T1 tumor cells as well as their capacity to trigger BMDC maturation (Supplementary Fig. 42).